Development and characterisation of orally disintegrating flurbiprofen tablets using SeDeM-ODT tool.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
07
06
2023
accepted:
21
08
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
In this study, SeDeM-ODT parametric tests were performed to determine the use of ludipress as a directly compressible tableting excipient for the development of a flurbiprofen orally disintegrating tablet. The preformulation features of different formulations (F1 -F9) were analyzed by the SeDeM-ODT tool which showed that all the powder blends were appropriate for direct compression since all the blends had index of good compressibility and bucodispersibility (IGCB) values above 5, signifying direct compression is the most appropriate method. The powder blend of the optimized formulation was assessed by the DSC-TGA technique. The optimization of nine different formulations blends of orally disintegrating tablets (ODTs) was prepared in various ratios by the implementation of design of experiments (DoE), using the central composite design by selecting ludipress (X1) (49-55%) and croscarmellose sodium (X2) (1-5%) while hardness, friability, and disintegration tests were selected as responses. The optimized formulations were evaluated by various tests and the results indicated that all the formulations were found to be in adequate range. Formulations were subjected to stability studies at accelerated states following ICH guidelines. Shelf life was found to be 51.144-56.186 months. Results of multiple-point dissolution studies revealed that formulations followed the Higuchi kinetic model. This study revealed that the SeDeM-ODT tool has been successfully used to determine the compression behavior of active compounds and their powder blends for the direct compression (DC) method in formulating flurbiprofen-ODT tablets.
Identifiants
pubmed: 39471194
doi: 10.1371/journal.pone.0309894
pii: PONE-D-23-13136
pmc: PMC11521243
doi:
Substances chimiques
Flurbiprofen
5GRO578KLP
Tablets
0
Powders
0
Excipients
0
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0309894Informations de copyright
Copyright: © 2024 Fatima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Expert Opin Drug Deliv. 2013 May;10(5):651-63
pubmed: 23387409
Eur J Pharm Biopharm. 2012 Apr;80(3):638-48
pubmed: 22245156
Eur J Pharm Sci. 2001 May;13(2):123-33
pubmed: 11297896
Acta Pharm. 2017 Jun 27;67(2):237-246
pubmed: 28590910
PLoS One. 2018 Sep 13;13(9):e0203846
pubmed: 30212557
Drug Dev Ind Pharm. 2017 Jun;43(6):889-901
pubmed: 28166428
PLoS One. 2020 Dec 31;15(12):e0244646
pubmed: 33382789
Saudi Pharm J. 2024 Mar;32(3):101957
pubmed: 38313822
PLoS One. 2021 Dec 9;16(12):e0261051
pubmed: 34882723
Eur J Pharm Sci. 2019 May 15;133:214-227
pubmed: 30951825
Pharm Dev Technol. 2018 Jun;23(5):512-519
pubmed: 28657404
J Young Pharm. 2010 Jul;2(3):234-9
pubmed: 21042477
Pak J Pharm Sci. 2021 Mar;34(2(Supplementary)):657-663
pubmed: 34275799
J Pharm Sci. 1963 Dec;52:1145-9
pubmed: 14088963
Biomed Res Int. 2021 Dec 24;2021:6618934
pubmed: 34977245
J Adv Pharm Technol Res. 2013 Jul;4(3):151-9
pubmed: 24083203
PLoS One. 2020 Feb 12;15(2):e0223201
pubmed: 32050259
Drug Dev Ind Pharm. 2014 Feb;40(2):222-36
pubmed: 23343308
Drug Des Devel Ther. 2023 Jan 26;17:261-272
pubmed: 36726738
Saudi Pharm J. 2014 Nov;22(5):433-44
pubmed: 25473332
J Pharm Sci. 1968 Feb;57(2):274-7
pubmed: 5641671